RZLTRezolute, Inc.
$4.64-47% 1Y
$4.64
$1.4052 weeks$10.94
RZLT in its own filings
RZLT's filing record carries 3 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
328
Events found in the filings · across 750 filings · the record starts in 2011
- Hard flags
- 3
Hard flags
- Most recent filing
- Oct 5, 2026
Most recent filing · Form 8-K
- Record starts
- Jul 11, 2011
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filinga quarter after the last one
- expected around Dec 24, 2026
- Change in certifying accountant3 occurrences
- 2024-03-14
- Late periodic report5 occurrences
- 2020-09-29
- Delisting notice / listing-rule failure3 occurrences
- 2023-11-22
- SEC comment-letter activity50 occurrences
- 2025-08-01
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Oct 5, 2026Announces FDA Recommendation to Hold a Pre-BLA.Regulation FD disclosure · press release
- Sep 24, 2026Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Business Update.Earnings release · press release
- Jun 2, 2026Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism.Regulation FD disclosure · press release
- May 12, 2026Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update.Earnings release · press release
- May 4, 2026Rezolute Announces Oral Presentation of Results.Regulation FD disclosure · press release
- Mar 24, 2026Update on its Congenital Hyperinsulinism Program Following FDA Meeting.Regulation FD disclosure · press release
- Feb 12, 2026Rezolute Reports Second Quarter Fiscal 2026.Earnings release · press release
- Jan 7, 2026Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism.Regulation FD disclosure · press release
- Nov 12, 2025Rezolute Investor Event: Ersodetug Development Program November 10, 2025.Regulation FD disclosure · press release
- Nov 6, 2025First Quarter Fiscal 2026 Financial Results and Provides Business Update.Earnings release · press release
- Oct 21, 2025Entry Into Material Definitive Agreement.Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…